Bretazenil is a GABA A-site ligand that acts as a partial agonist at the GABA_A receptor and has been widely used in pharmacological research. Its unique partial agonist profile allows researchers to activate benzodiazepine receptors without producing the full sedative, hypnotic, and muscle-relaxant effects seen with classical benzodiazepines. This makes bretazenil a valuable tool for studying the relationship between receptor activation and behavioral outcomes.